Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals

Benzinga_recent_news02-19

Enveric Biosciences (NASDAQ:ENVB) on Thursday shared new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612821288?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/19/Brain-to-Heart-Growth.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-02-19 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612821288","market":"us","top_or_hot":-1,"title":"Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals","media":"Benzinga_recent_news","content":"<div>\n<p>Enveric Biosciences (NASDAQ:ENVB) on Thursday shared new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50716378/enveric-advances-lead-drug-with-new-findings-on-key-brain-receptor-signals\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnveric Advances Lead Drug With New Findings On Key Brain Receptor Signals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-19 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/02/50716378/enveric-advances-lead-drug-with-new-findings-on-key-brain-receptor-signals><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Enveric Biosciences (NASDAQ:ENVB) on Thursday shared new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50716378/enveric-advances-lead-drug-with-new-findings-on-key-brain-receptor-signals\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENVB","symbol_name":"Enveric Biosciences","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/02/50716378/enveric-advances-lead-drug-with-new-findings-on-key-brain-receptor-signals","article_id":"2612821288","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/19/Brain-to-Heart-Growth.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/02/50716378/enveric-advances-lead-drug-with-new-findings-on-key-brain-receptor-signals","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612821288","pubTimestamp":1771506000,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Enveric shares new EB-003 data showing dual pathway activity as the company advances toward clinical testing.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ENVB":"Enveric Biosciences","BK4007":"制药","01611":"新火科技控股","BK1612":"加密货币概念","BK1167":"电子制造服务"},"translate_title":"Enveric在关键脑受体信号方面取得新发现，推进先导药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENVB":1,"01611":0.69},"content_text":"Enveric Biosciences (NASDAQ:ENVB) on Thursday shared new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor.\nEB-003 is being developed to be a non-hallucinogenic neuroplastogen intended to support streamlined treatment paradigms, including potential at-home administration.\nEnveric Biosciences continues to advance EB-003 through IND-enabling studies.\nMultiple independent, peer-reviewed studies have previously shown that selective activation of 5-HT₂A receptor, by either Gq-biased or β-arrestin–biased agonists, can independently produce antidepressant- and anxiolytic-like effects in preclinical models.\nThe new data were generated using proprietary bioluminescence resonance energy transfer (BRET) assays.\nEnveric developed and validated in-house BRET assays to characterize EB-003's intracellular signaling profile because commercial assays capable of reliably measuring pathway-specific 5-HT₂A signaling were not available.\nThe data demonstrate biologically relevant engagement of both Gq and β-arrestin pathways.\nEnveric's new data also indicate that EB-003 exhibits a modest preference toward β-arrestin over Gq signaling relative to serotonin, the native ligand of the receptor.\nOngoing research is exploring the mechanistic significance of this apparent bias.\nA recently published study in Nature employing BRET assays and complementary techniques provides additional mechanistic clarity regarding signaling downstream of 5-HT₂A.\nThe study reports that Gi signaling downstream of 5-HT₂A was required for hallucinogenic effects in the experimental models evaluated, while Gq signaling mediated antidepressant- and anxiolytic-like benefits in preclinical systems.\nThese findings indicate that therapeutic benefit and hallucinations may arise from distinct intracellular pathways.\n\"Growing mechanistic clarity around 5-HT₂A signaling strengthens confidence in the scientific foundation of our platform,\" said Joseph Tucker, CEO of Enveric Biosciences.\nDr. Tucker added, \"Enveric is planning additional BRET testing of EB-003, including the Gi pathway, to further characterize its unique signaling mechanisms.\"\nCEO Tucker exclusively told Benzinga, “Mechanistic uncertainty is a major reason CNS drugs fail. Understanding the signaling biology before clinical trials begin helps reduce that risk.\"\n When talking about hallucinations, he said, \"We haven't tested EB-003 in humans yet, so we can't make clinical claims, although our preclinical work using a proxy for hallucinations is encouraging…We do have more work to do on the newly singled out pathways, to see if or how EB-003 is engaging with them.\"\n \"Our goal is a therapy compatible with standard prescribing rather than monitored sessions. Whether it can be used at home will depend entirely on clinical safety and regulatory review,\" Tucker commented.\nDiscussing the next milestones, Tucker said, “We're advancing IND-enabling studies while expanding pathway characterization so that we enter clinical testing with a well-understood mechanism.\"\nENVB Price Action: Enveric shares are up 9.82% at $2.46 in premarket trading on Thursday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612821288","isCrawlerRequest":true}